Application of Immunotherapy in the Treatment of Solid Tumors

Wenhan Zhang

doi:10.62051/41wndp04

Authors

Wenhan Zhang

DOI:

https://doi.org/10.62051/41wndp04

Keywords:

Immunotherapy; cancer; challenge.

Abstract

Cancer is one of the major diseases that seriously threaten human life and health at present, and the number of deaths due to cancer every year ranks in the top 2 of all diseases. In recent years, the malignant tumor is increasing year by year, so it is necessary to explore new therapeutic methods. Immunotherapy of tumor cells is one of the hot topics in tumor therapy, which aims to destroy tumor cells by activating or regulating the immune system of patients. More and more tumor immunotherapy drugs have been successfully developed and marketed, bringing the hope of long-term survival to patients. However, like other tumor drug therapy, tumor immunotherapy has brought huge benefits to some tumor patients and made people full of expectations, but it also faces many difficulties and challenges in pre-clinical research and clinical application. This article summarizes the application and challenge of immunotherapy in solid tumors.

Downloads

Download data is not yet available.

References

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249.

[2] Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May-Jun;74(3):229-263.

[3] Huang Qing, Xue Chang, Hu Sheng. Progress of FDA-approved cancer treatment drugs in 2023 [J]. Cancer Prevention and Treatment Research, 2019,51(7):542-545.

[4] Zhao Lu, Zhang Zhengfeng, Waang Da zhen, et al. Application of immunotherapy in solid tumors [J]. Journal of Practical Oncology, 2019,38(1):55-61.

[5] Antonarakis ES, Piulats JM, Gross-Goupil M, et al. Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. J Clin Oncol. 2020 Feb 10;38(5):395-405.

[6] O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, Queirolo P, Lundgren L, Mikhailov S, Roman L, Verschraegen C, Humphrey R, Ibrahim R, de Pril V, Hoos A, Wolchok JD. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol. 2010 Aug;21(8):1712-1717.

[7] Li Tao, Zhang Kan, Yang Wenyu, et al. Clinical application of immune checkpoint inhibitor CTLA-4 in the treatment of solid tumors [J]. Journal of Concord Medicine, 2019,14(3):652-659.

[8] Liu Yingfeng, SONG Yagang, Miao Mingsan. Research progress of oncolytic virus as antitumor drug in the treatment of liver cancer [J]. Central South Pharmacy, 2019,22(7):1872-1876.

[9] 9. Zhu Guanglin, WU Shuai, Wu Jinsong. Research progress of oncolytic virus in the treatment of brain glioma [J]. Chinese Journal of Surgery, 2019,62(1):76-81.

[10] Nassiri F, et al. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Nat Med. 2023 Jun;29(6):1370-1378.

[11] Monberg TJ, Borch TH, Svane IM, Donia M. TIL Therapy: Facts and Hopes. Clin Cancer Res. 2023 Sep 1;29(17):3275-3283. doi: 10.1158/1078-0432.CCR-22-2428. PMID: 37058256.

[12] Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988 Dec 22;319(25):1676-80.

[13] Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer. 2022 Dec;10(12):e005755.

[14] Medina T, Chesney J A, Whitman E, et al. 119O Long-term efficacy and patterns of response of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: A 4-year analysis of the C-144-01 study. Immuno-Oncol Tech, 2023, 20: 100591.

[15] Xing Xiaofang, Wang Zifan, Wu Ming, et al. Research frontiers and challenges of immune cell therapy for solid tumors [J/OL]. Chinese Science Bulletin,1-18[2024-09-09].

[16] Yang Wenqian, Wang Yuze. Research progress of immunotherapy in osteosarcoma [J]. Cancer, 2019,42(06):285-294.

[17] Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021 Oct 14;184(21):5309-5337. doi: 10.1016/j.cell.2021.09.020. Epub 2021 Oct 7. Erratum in: Cell. 2022 Feb 3;185(3):576.

[18] Green AK. Challenges in Assessing the Cost-effectiveness of Cancer Immunotherapy. JAMA Netw Open. 2021 Jan 4;4(1):e2034020.